|
Your brokerage says you own "pharma."
It's wrong.
What they're calling one industry is actually two industries moving in opposite directions at different speeds. And the gap between them is one of the largest divergences our engine has ever scored.
We ran both through our 8-dimension AI disruption engine — the same system that scores 28 industries across 166 cross-effects, 5 time horizons, and 3 scenario modes.
The results weren't close.
| Dimension |
Big Pharma |
Biotech-AI |
| AI Adoption |
0.18 |
0.51 |
| Velocity |
0.82 |
0.98 |
| Resistance |
0.87 |
0.70 |
| Competitive Moat |
+0.85 |
+0.65 |
Big Pharma is barely started (18% of ceiling) but has an impenetrable moat. Biotech-AI is already halfway there with near-maximal velocity — but historically gets acquired before reaching scale.
The full report breaks down all 8 dimensions, maps 12 cross-industry cascade effects (when pharma moves, 6 other industries in your portfolio feel it), and identifies the trillion-dollar question: if AI cuts drug discovery from $2.5 billion to $250 million, who captures that value?
This is the kind of analysis our engine produces for all 28 industries. The full matrix shows you where every industry sits across 1, 2, 3, 5, and 10-year horizons — and what happens to the other 27 when any one of them moves.
|
IN THIS REPORT
• The 8-dimension engine comparison (full scoring table)
• Why Big Pharma's moat is strengthening, not breaking
• Rentosertib: the first fully AI-designed drug approaching FDA approval
• 12 cross-industry cascade effects that touch your other holdings
• The bull/bear case: who captures the $2.25 billion cost savings?
• AlphaGenome, Evo 2, and the "ChatGPT moment" for biology
|
Your next industry deep dive arrives in 2 weeks.
— AI Stock Market Impacts Research
|